219 related articles for article (PubMed ID: 17440057)
1. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.
Binder M; Vögtle FN; Michelfelder S; Müller F; Illerhaus G; Sundararajan S; Mertelsmann R; Trepel M
Cancer Res; 2007 Apr; 67(8):3518-23. PubMed ID: 17440057
[TBL] [Abstract][Full Text] [Related]
2. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
3. IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies.
Baan CC; Boelaars-van Haperen MJ; van Riemsdijk IC; van der Plas AJ; Weimar W
Transplant Proc; 2001 May; 33(3):2244-6. PubMed ID: 11377516
[No Abstract] [Full Text] [Related]
4. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
Madsen M; Svendsen UG
Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies.
Kircher B; Lätzer K; Gastl G; Nachbaur D
Clin Exp Immunol; 2003 Dec; 134(3):426-30. PubMed ID: 14632747
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.
Goebel J; Stevens E; Forrest K; Roszman TL
Transpl Immunol; 2000 Nov; 8(3):153-9. PubMed ID: 11147695
[TBL] [Abstract][Full Text] [Related]
9. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
[TBL] [Abstract][Full Text] [Related]
10. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation.
Wang Z; Shi BY; Qian YY; Cai M; Wang Q
Clin Exp Immunol; 2009 Mar; 155(3):496-503. PubMed ID: 19141125
[TBL] [Abstract][Full Text] [Related]
11. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab.
Baudouin V; Crusiaux A; Haddad E; Schandene L; Goldman M; Loirat C; Abramowicz D
Transplantation; 2003 Aug; 76(3):459-63. PubMed ID: 12923429
[TBL] [Abstract][Full Text] [Related]
12. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody.
Leonard PA; Woodside KJ; Gugliuzza KK; Sur S; Daller JA
Transplantation; 2002 Dec; 74(12):1697-700. PubMed ID: 12499883
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab.
Mottershead M; Neuberger J
Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
[TBL] [Abstract][Full Text] [Related]
14. Clinical advances in therapies targeting the interleukin-2 receptor.
Church AC
QJM; 2003 Feb; 96(2):91-102. PubMed ID: 12589007
[No Abstract] [Full Text] [Related]
15. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
16. Generation of Affibody ligands binding interleukin-2 receptor alpha/CD25.
Grönwall C; Snelders E; Palm AJ; Eriksson F; Herne N; Ståhl S
Biotechnol Appl Biochem; 2008 Jun; 50(Pt 2):97-112. PubMed ID: 18284375
[TBL] [Abstract][Full Text] [Related]
17. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
[No Abstract] [Full Text] [Related]
18. A review of interleukin-2 receptor antagonists in solid organ transplantation.
Berard JL; Velez RL; Freeman RB; Tsunoda SM
Pharmacotherapy; 1999 Oct; 19(10):1127-37. PubMed ID: 10512062
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab.
Du J; Yang H; Zhang D; Wang J; Guo H; Peng B; Guo Y; Ding J
J Immunol; 2010 Feb; 184(3):1361-8. PubMed ID: 20032294
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a monoclonal antibody directed against the NH2 terminal area of interleukin-2 (IL-2) and inhibiting specifically the binding of IL-2 to IL-2 receptor beta chain (IL-2R beta).
Moreau JL; Bossus M; de Groote D; François C; Jacques Y; Tartar A; Thèze J
Mol Immunol; 1995 Oct; 32(14-15):1047-56. PubMed ID: 8544854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
